Christopher R. Fenimore Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Christopher R. Fenimore is EVP Finance CFO of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 18,300 shares of REGN, which is worth approximately $12.7 Million. The most recent transaction as insider was on Oct 03, 2022, when has been sold 3,346 shares (Common Stock) at a price of $724.0 per share, resulting in proceeds of $2,422,504. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 18.3K

12.51% 3M change

12.51% 12M change

Total Value Held $12.7 Million

Christopher R. Fenimore Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 03 2022	SELL Open market or private sale	$2,422,504 $724.0 p/Share	3,346 Reduced 15.48%	18,269 Common Stock
Apr 08 2022	SELL Payment of exercise price or tax liability	$4,127,193 $736.21 p/Share	5,606 Reduced 17.4%	26,615 Common Stock
Apr 08 2022	BUY Exercise of conversion of derivative security	$3,077,222 $413.05 p/Share	7,450 Added 19.86%	30,066 Common Stock
Mar 31 2022	SELL Payment of exercise price or tax liability	$6,066,367 $700.99 p/Share	8,654 Reduced 25.89%	24,771 Common Stock
Mar 31 2022	BUY Exercise of conversion of derivative security	$4,956,600 $413.05 p/Share	12,000 Added 27.51%	31,628 Common Stock
Dec 11 2021	SELL Payment of exercise price or tax liability	$179,372 $664.34 p/Share	270 Reduced 1.26%	21,122 Common Stock
Dec 08 2021	BUY Grant, award, or other acquisition	-	1,859 Added 8.0%	21,392 Common Stock

Aug 23 2021	SELL Open market or private sale	$3,160,624 $661.08 p/Share	4,781 Reduced 14.7%	27,739 Common Stock
Aug 20 2021	BUY Exercise of conversion of derivative security	$2,418,255 $179.13 p/Share	13,500 Added 29.34%	32,520 Common Stock
Dec 09 2020	BUY Grant, award, or other acquisition	-	2,719 Added 11.41%	21,102 Common Stock
Jul 21 2020	SELL Open market or private sale	$2,386,073 $643.32 p/Share	3,709 Reduced 17.49%	17,501 Common Stock
Jul 20 2020	SELL Payment of exercise price or tax liability	$4,124,190 $655.57 p/Share	6,291 Reduced 24.89%	18,986 Common Stock
Jul 20 2020	BUY Exercise of conversion of derivative security	$1,412,849 $115.58 p/Share	12,224 Added 36.56%	21,210 Common Stock
Jun 16 2020	SELL Open market or private sale	$2,094,341 $588.96 p/Share	3,556 Reduced 18.88%	15,277 Common Stock
Jun 15 2020	SELL Payment of exercise price or tax liability	$2,157,593 $587.9 p/Share	3,670 Reduced 18.06%	16,653 Common Stock
Jun 15 2020	BUY Exercise of conversion of derivative security	$388,749 $41.33 p/Share	9,406 Added 33.31%	18,833 Common Stock
Apr 01 2020	SELL Open market or private sale	$584,820 $487.35 p/Share	1,200 Reduced 8.39%	13,097 Common Stock
Apr 01 2020	BUY Exercise of conversion of derivative security	$36,756 $30.63 p/Share	1,200 Added 7.74%	14,297 Common Stock

CRF

Christopher R. Fenimore

EVP Finance CFO

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account